Comparing Liposomal and Standard Bupivacaine for Pain Relief After Thoracoscopic Lung Surgery

What this Trial Is About

Researchers are investigating the effectiveness and safety of a nerve block using bupivacaine liposome for pain relief after thoracoscopic lobectomy, a minimally invasive lung surgery. The study also explores whether bupivacaine liposome is not worse than the standard bupivacaine in managing postoperative pain. This trial is a phase 4, randomized, double-blind study focused on improving pain control after lung surgery. Participants receive either a mixture of liposomal bupivacaine combined with standard bupivacaine or standard bupivacaine alone, administered via thoracic paravertebral nerve block at multiple spinal levels under ultrasound guidance. All patients undergo general anesthesia with intravenous agents and muscle relaxants during surgery, followed by postoperative pain management including patient-controlled intravenous analgesia using sufentanil. After surgery, patients are monitored in the post-anesthesia care unit until they meet recovery criteria before moving to the ward. During the study, patients will be regularly assessed for pain using a numeric rating scale over 48 hours and beyond, quality of recovery scores at 24, 48, and 72 hours, and opioid consumption within 72 hours after surgery. Standard monitoring includes heart rate, blood pressure, oxygen levels, and neuromuscular function. Researchers track pain relief effectiveness, recovery quality, and safety of the nerve block treatments over the postoperative period to better understand pain control methods after thoracoscopic lung surgery.

Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain